London: On July 25, Bavarian Nordic (BAVA.CO) CEO stated that the company was in talks to potentially expand production capacity. The Copenhagen-based vaccine maker has a vaccine that goes by the brand name Jynneos, Imvamune, or Imvanex – depending on geography. It has U.S. and European approval for its use in the prevention of monkeypox, as well as closely-related smallpox. Bavarian has an annual production capacity of 30 million doses, including the monkeypox vaccine and other vaccines it makes.
